Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)
| 289.48 Delayed Data As of Jan 27 |  -11.14 / -3.71%Today’s Change | 52.33 Today|||52-Week Range 315.45 | -0.27% Year-to-Date |
Latest MDGL News | Press Releases
| This "Golden" Technical Indicator is Triggering Across the Market Jan 26 / Zacks.com - Paid Partner Content | Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA Jan 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 300.64 |
| Today’s open | 301.52 |
| Day’s range | 288.92 - 303.44 |
| Volume | 222,274 |
| Average volume (3 months) | 502,482 |
| Market cap | $5.2B |
Data as of 3:59pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -11.71% |
| Earnings growth (this year) | -14.99% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 26.54 |
Competitors
Data as of 3:59pm ET, 01/27/2023
Financials
| Next reporting date | March 1, 2023 |
| EPS forecast (this quarter) | -$4.62 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$241.8M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters West Conshohocken, Pennsylvania |
Forecasts
